DEA Opposes Reopening Marijuana Rescheduling Hearing in Filing

The DEA's position, as reported

The DEA told a judge the request to reopen the marijuana rescheduling hearing should be denied, and described the accompanying discovery demand as a "fishing expedition."

That's all the public record supports so far. The Marijuana Herald reported the filing on Oct. 21, 2026, and CannIntel had not independently reviewed the underlying document at publication.

"Fishing expedition" is a familiar litigation phrase. It means a party is demanding broad documents or testimony in the hope something useful turns up, rather than pursuing evidence tied to a specific issue.

What the signal doesn't tell us

The report leaves out the details that would let anyone judge the merits: who filed the request, what it seeks, and which judge will rule.

We won't guess. Until the docket is in hand, these items stay open:

• The identity of the party or parties seeking to reopen the hearing.
• The specific categories of documents or testimony in the discovery request.
• The name of the presiding judge and any ruling deadline.
• Whether the DEA's filing is a formal opposition brief or a narrower response.

Not yet confirmed. Not yet knowable.

Why discovery is the pressure point

Discovery fights decide how long a formal rulemaking hearing runs, and the DEA has every incentive to keep this one narrow.

Rescheduling under the Controlled Substances Act runs through a hearing on the record before an administrative law judge, a process far slower than ordinary notice-and-comment rulemaking. Opening the door to document demands tends to widen the factual record, and a wider record means more time and more grounds for later appeal.

The DEA's argument, as reported, is that the request is a search for material rather than a targeted demand tied to a defined dispute.

That framing is a standard defense posture. It's also a tell: an agency that expects to win on the merits usually prefers a short record.

How the proceeding got here

The Schedule III proposal dates to a May 2024 notice of proposed rulemaking, and the hearing process that followed has been stop-and-start.

A May 21, 2024 Justice Department notice proposed moving marijuana from Schedule I to Schedule III, following a health-based recommendation from HHS. The hearing that was supposed to test that proposal was stayed in early 2025 and has been a procedural battleground since.

For a fuller timeline, see the CannIntel topic hub on DEA marijuana rescheduling.

What's at stake for operators and investors

A Schedule III move would end the 280E tax penalty for state-licensed operators, so every month of procedural delay carries a measurable cost.

Section 280E of the tax code bars businesses that traffic in Schedule I or II substances from deducting ordinary expenses. Moving marijuana to Schedule III would remove that bar. It wouldn't make state-licensed sales federally legal.

MSOs have priced a rescheduling outcome into their valuations for years. A reopened hearing with open-ended discovery would push that date out, which is the practical reason this filing matters beyond the courtroom.

Patients and researchers are affected too. Schedule III status would ease some federal research restrictions, though not the FDA approval pathway for products.

What to watch next

The judge's ruling on the request, and the scope of any discovery she or he allows, will signal whether the hearing stays on a short track.

Three markers are worth tracking:

1. A written ruling granting or denying the request to reopen.
2. Any narrowing order if the judge allows limited discovery.
3. A reply brief from the requesting party, which would finally name what it is after.

Our read: the DEA's tone suggests it sees this as a threat to the schedule, not a nuisance. The next signal is the judge's order. We'll publish the docket details once we have the filing.